Beyond Air, Inc. Deferred Tax Assets, in Process Research and Development
Beyond Air, Inc. (XAIR) had Deferred Tax Assets, in Process Research and Development of $2.51 million as of 2026-03-31, per its 10-K filed 2026-06-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-06-26
- 2026-03-31: Deferred Tax Assets, in Process Research and Development $2.51M.
- 2025-03-31: Deferred Tax Assets, in Process Research and Development $2.20M.
- 2024-03-31: Deferred Tax Assets, in Process Research and Development $2.14M.
- 2023-03-31: Deferred Tax Assets, in Process Research and Development $1.62M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2026-03-31 | $2.51M 10-K · filed 2026-06-26 |
| 2025-03-31 | $2.20M 10-K · filed 2026-06-26 |
| 2024-03-31 | $2.14M 10-K · filed 2025-06-20 |
| 2023-03-31 | $1.62M 10-K · filed 2024-06-24 |
| 2022-03-31 | $1.23M 10-K · filed 2023-06-22 |
| 2021-03-31 | $939.00K 10-K · filed 2022-06-29 |
| 2020-03-31 | $524.00K 10-K · filed 2021-06-10 |
| 2019-03-31 | $243.00K 10-K · filed 2020-06-23 |
| 2018-03-31 | $762.00K 10-KT · filed 2018-06-15 |
| 2017-12-31 | $667.00K 10-KT · filed 2018-06-15 |
| 2016-12-31 | $153.00K 10-KT · filed 2018-06-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |